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Abstract
Background: Hormone therapy plus radiotherapy significantly decreases recurrences and mortality of patients
affected by locally advanced prostate cancer. In order to determine if difference exists according to the hormonal
treatment duration, a literature-based meta-analysis was performed.
Methods: Relative risks (RR) were derived through a random-effect model. Differences in primary (biochemical
failure, BF; cancer-specific survival, CSS), and secondary outcomes (overall survival, OS; local or distant recurrence,
LR/DM) were explored. Absolute differences (AD) and the number needed to treat (NNT) were calculated.
Heterogeneity, a meta-regression for clinic-pathological predictors and a correlation test for surrogates were
conducted.
Results: Five trials (3,424 patients) were included. Patient population ranged from 267 to 1,521 patients. The longer
hormonal treatment significantly improves BF (with significant heterogeneity) with an absolute benefit of 10.1%,
and a non significant trend in CSS. With regard to secondary end-points, the longer hormonal treatment
significantly decrease both the LR and the DM with an absolute difference of 11.7% and 11.5%. Any significant
difference in OS was observed. None of the three identified clinico-pathological predictors (median PSA, range
9.5-20.35, Gleason score 7-10, 27-55% patients/trial, and T3-4, 13-77% patients/trial), did significantly affect
outcomes. At the meta-regression analysis a significant correlation between the overall treatment benefit in BF,
CSS, OS, LR and DM, and the length of the treatment was found (p≤0.03).
Conclusions: Although with significant heterogeneity (reflecting different patient’ risk stratifications), a longer
hormonal treatment duration significantly decreases biochemical, local and distant recurrences, with a trend for
longer cancer specific survival.
Background
Androgen-deprivation remains the cornerstone of treat-
ment for patients with hormone-sensitive advanced pros-
tate cancer [1]. The combination of hormonal suppression
and the radiotherapy is able to significantly decrease the
recurrences and the mortality of patients affected by
locally advanced prostate cancer. Substantial toxicities
were also identified when hormone therapy was used.
[2-11]. A recently conducted meta-analysis has demon-
strated an overall absolute benefit of 7.5-10% in favor of
the addition of the hormone therapy to in terms of bio-
chemical failure and clinical progression free survival [12].
The optimal duration of androgen ablation therapy is
still controversial despite a growing number of prognos-
tic factors that have been shown to predict disease
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outcome [13]. In all prospective randomized trials, long
term hormonal therapy (more than 2 years) improves
survival in patients with locally high risk (Gleason score
≥ 8, median PSA ≥ 20, stage ≥ T3) advanced prostate
cancer. This strategy, however, is also associated with an
increased risk of morbidities, such as osteoporosis, dia-
betes, depression, dislipidemia and abdominal obesity
[14,15].
The value of short-term hormonal treatment in
patients with intermediate risk disease (Gleason score ≥
7, median PSA ≥ 10, stage ≥ T2c) has also been detected
[16,17], although its role in high-risk disease is still con-
troversial. Nevertheless, short courses of hormonal
suppression have been shown to be very effective in
downstaging localized disease. Surgical series have pro-
vided some histopathological confirmation, with signifi-
cant decreases in margin-positive rates in prostatectomy
after neoadjuvant hormonal therapy [18,19].
In order to determine if difference exists between a
shorter and a longer hormone therapy (HT) in combina-
tion with radiotherapy, a literature based meta-analysis
was conducted.
Methods
The analysis was conducted following 4 steps: definition
of the outcomes (definition of the question the analysis
was designed to answer), definition of the trial selection
criteria, definition of the search strategy, and a detailed
description of the statistical methods used [20,21].
Outcome definition
The combination of a short-term HT (ST) and RT was
considered as the experimental arm and a long-term
HT (LT) and RT as the standard comparator. Analysis
was conducted in order to find significant differences in
primary and secondary outcomes, according to a pre-
viously published meta-analysis and the reported
sequence and definitions in the selected trials. Primary
outcomes for the magnitude of the benefit analysis were
both the Biochemical Failure (BF, time between rando-
mization and PSA increase) and the CSS (time between
randomization and death for prostate cancer). Secondary
end-points were: OS (time between randomization and
death for any cause), local failure rate (LF) and distant
metastases rate (DM).
Search strategy
Deadline for trial publication and/or presentation was
September 30th, 2010. Updates of Randomized Clinical
Trials (RCTs) were gathered through Medline (PubMed:
http://www.ncbi.nlm.nih.gov/PubMed), ASCO (American
Society of Clinical Oncology, http://www.asco.org),
ESMO (European Society for Medical Oncology, http://
www.esmo.org), FECS (Federation of European Cancer
Societies, http://www.fecs.be), and ASTRO (American
Society for Therapeutic Radiology and Oncology, http://
www.astro.org) website searches. Key-words used for
searching were: adjuvant hormone therapy, prostate
cancer, radiotherapy, duration, longer, shorter, review,
metanalysis, meta-analysis, pooled analysis, randomized,
phase III, comprehensive review, systematic review. In
addition to computer browsing, review and original papers
were also scanned in the reference section to look for
missing trials. Furthermore, lectures at major meetings
(ASCO, ESMO, ECCO, and ASTRO) having ‘hormone
treatment and radiotherapy for prostate cancer’ as the
topic were checked. No language restrictions were applied.
Trial identification criteria
All prospective phase III RCTs published in peer-
reviewed journals or presented at the ASCO, ECCO,
ESMO and ASTRO meetings until September 2010,
in which previously untreated patients with locally
advanced prostate cancer were prospectively randomized
to short or long-HT plus radiotherapy were gathered.
Any trial exploring a shorter versus a longer HT
(regardless of their absolute values) in combination with
RT for the treatment of LAPC was considered eligible.
Data extraction
The number of events for primary and secondary end-
points were extracted; the last trial’s available update
was considered as the original source. All data were
reviewed and separately computed by five investigators
(F.Cu., E.B., D.G., I.S., and P.C.).
Data synthesis
The log of relative risk ratio (RR) was estimated for each
considered endpoint [22], and 95% Confidence Intervals
(CI) were derived [23]. A random-effect model accord-
ing to the DerSimonian method was preferred to the
fixed, given the known clinical heterogeneity of trials
[24-26]; a Q-statistic heterogeneity test was used
[27-29]. Absolute benefits for each outcome were calcu-
lated (i.e. absolute benefit=exp {RR × log[control survi-
val]} - control survival [30]; modified by Parmar and
Machin [31]). The number of patients needed to be
treated for one single beneficial patient was determined
(NNT: 1/[(Absolute Benefit)/100]) [32]. Results were
depicted in all figures as conventional meta-analysis for-
est plots; a RR <1.0 indicates fewer events in the experi-
mental arm. In order to find possible correlations
between outcome effect and negative prognostic factors
(selected among trials’ reported factors: the median
PSA, the Gleason score of 7-10 and the T3-4), a meta-
regression approach was adopted (i.e. regression of the
selected predictor on the Log RR of the corresponding
outcome); the time delay in months for each considered
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trial between the duration of the short and the long
treatment arm was considered in the meta-regression
analysis as treatment predictor as well. Calculations
were accomplished using the Comprehensive Meta-
Analysis Software, version v. 2.0 (CMA, Biostat, Engle-
wood, NJ, USA).
Correlation
Potential correlations to test surrogacy between primary
and secondary end-points, were explored according to
regression between the calculated RRs and their logs for
each outcome.
Results
Selected trials
Twelve trials (7,811 patients) were identified (Figure 1)
[2-11,33-37]. Seven RCTs were excluded because HT
was administered in one arm only (4,387 patients)
[2-11,33], question already answered in a previous meta-
analysis [38]. Five RCTs were included in the meta-
analysis, all evaluable for BF (3,424 patients) [7,34-37].
According to the trial’ selection, the shorter approach
ranged from 3 to 6 months, while the longer from 8 to
36 months; trials characteristics are listed in Table 1.
Four were evaluable for CSS, OS, and three for LR and
DM [34-37]. Toxicity analysis was not performed
because data about toxicity were available only in two
studies. Median follow-up ranged from 3.7 to 10 years.
Three predictors were identified: median PSA (range
9.5-20.35), Gleason score 7-10 (range 27-55% of
patients/trial) and T3-4 (range 13-77% patients/trial).
Combined Analysis
With regard to the primary outcomes, the longer HT
significantly decreased biochemical failure over the
shorter HT with an absolute benefit of 10.1% (RR 1.32,
95% CI 1.09, 1.60, p = 0.004), corresponding to 9-10
patients to be treated for one to benefit, although with
significant heterogeneity (p = 0.003) (Table 2). A non
significant trend in the prostate-cancer specific survival
was found (RR 1.21, 95% CI 0.82, 1.79, p = 0.32) when
adopting a longer HT, without significant heterogeneity.
Concerning the secondary outcomes, the longer HT sig-
nificantly reduced both the risk of local recurrences (RR
1.87, 95% CI 1.22, 2.86, p = 0.004) and the risk of dis-
tant metastases (RR 1.77, 95% CI 1.16, 2.69, p = 0.007)
by 11.7% and 11.5%, without significant heterogeneity,
which translate into 9 patients to be treated for one to
benefit (Table 2). No significant differences in overall
survival were observed by comparing the two arms
(Table 2).
According to the performed meta-regression analysis,
none of the considered negative predictors significantly
affected outcome. Conversely, the treatment predictor
(the time delay) significantly correlates with all explored
outcomes (Table 3).
Correlation Analysis
The correlation analysis was performed in the 4 RCTs,
in which BF could be considered as a potential surrogate
endpoint [34-36]. The regression between the RR of BF
and the Log of CSS (p = 0.005) was statistically signifi-
cant. The regression between the RR of OS and the Log
of BF and CSS was not significant (p = 0.052 and p =
0.16, respectively). The regression of the RR of DM and
the Log of BF and CSS was statistically significant (p =
0.029 and (p = 0.041, respectively). The regression of
the RR of LR and the Log of BF was statistically signifi-
cant (p = 0.049).
Discussion
Although the number of studies is small to produce reli-
able estimates, the data presented herein strengthen the
role of the hormone-therapy duration in patients candi-
dates to receive androgen suppression in association
with radiotherapy for locally advanced prostate cancer
(Table 2 Figures 2, 3).
Hormonal suppression in patients affected by locally
advanced prostate cancer candidates to receive exclusive
radiotherapy is able to improve outcome, as a series of
trials recently demonstrated; according to the results of
our previous meta-analysis, hormonal suppression plus
radiotherapy significantly decreases recurrence and mor-
tality of patients with localized prostate cancer. The
magnitude of this survival benefit ranges from 4.9% to
5.5% for OS and CSS, respectively, which translates into
20 and 18 NNT. Local and distant relapse were signifi-
cantly decreased by hormonal treatment, by 36% and
28%, without significantly affect toxicity [38].
5 RCTs included in the 
meta-analysis (3,424 pts)
12 Potential RCTs identified
(7,811 pts)
7 RCTs excluded because
of exclusion criteria 
(HT in one arm only)
(4,387 pts)*
5 RCTs evaluable for BF 
(3,424 pts)
Primary Outcomes Secondary Outcomes
4 RCTs evaluable for CSS 
(3,128 pts)
Data not available for 
1 RCT (296 pts)
3 RCTs evaluable for LR and DM
(2,852 pts)
Data not available for 
2 RCTs (572 pts)
4 RCTs evaluable for OS
(3,128 pts)
Data not available for 
1 RCT (296 pts)
Figure 1 Outline of the search - Flow diagram. RCTs: randomized
clinical trials; pts: patients; HT: hormone therapy; BF: biochemical
failure; OS: overall survival; CSS: cancer specific survival; LR: local
recurrences; DM: distant metastases.
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Although the use of adjuvant hormonal therapy has
been shown in randomized trials to improve outcomes,
two issues still need to be clarified: 1) the optimal hor-
mone therapy duration and 2) the impact of the radia-
tion dose on outcome and local control. Within this
context, the current meta-analysis was aimed to assess if
difference exist between a shorter and longer androgen
suppression, according to the trialist’ definition. The
pooled results of the considered trials show that a
longer treatment approach improves all outcomes when
compared to a shorter one (Table 2 Figure 2, 3). In par-
ticular, BF is significantly reduced when hormone-ther-
apy is administered in a longer fashion, with an overall
absolute difference of 10.1%, which corresponds to only
9-10 patients needed to be treated for one to benefit
(Table 2). Although the meta-regression analysis could
be not valid given the small number of gathered trials,
the benefits present across all outcomes are provided in
favour of a longer strategy, regardless of any of the
selected negative predictors, suggesting an overall effect
independent by any clinico-pathological feature. Conver-
sely to the these predictors, the lenght of treatment
seems to significantly affect all outcomes, suggesting the
even more independent value of a longer approach
(Table 3). Although this interpretation should be sof-
tened, given the limitations related to a meta-regression
analysis, a further individual patient data meta-analysis
could eventually clarify if a particular subset of patients
would better benefit of such approach. Moreover, these
conclusion should be driven only when an homogenous
risk classes classification was likely to be prospectively
adopted in all analyzed trials. Indeed, the significant het-
erogeneity in the selected primary outcome can easily
reflect that the magnitude of the reported benefit is dif-
ferent across trials, and this can likely be a clear effect
of the different patient’ selection.
The adopted meta-analytic method did not allow to
extract patients’ subgroups data from those trials where
either low, intermediate and high risk patients were
accrued together. For example, no advantage for longer
duration was found in those trials enrolling low risk
Table 1 Trials’ Characteristics
Authors Pts Dose RT (Gy) Arms (mo.) Median
F.U.
End-Points Median
PSA (ng/mL)
N° of pts (%)
Primary Secondary Gleason
Score 7-10
T3-T4
Laverdiere
et al
148
148
64 5 (AS)
10 (AS)
3.7 yrs BDFS, CDFS - 11.9
12.7
82 (27.6) 40 (13.4)
Crook et al 177
184
66 3 (GF)
8 (GF)
79 mo. OS, CSS, DFS - 8.9
10.1
178 (49.3) 48 (13.2)
Horwitz
et al
763
758
65-70 4 (GF)
24 (GF)
10 yrs DFS OS, BF, DMF 20.8
19.8
838 (55.1) 829 (54.5)
Bolla
et al
483
487
70 6 (CAB)
36 (CAB)
5.2 yrs OS, CPFS, DS, BPFS - 18.8
18.8
479 (49.3) 754 (77.7)
Armstrong
et al
127
134
50-74 4 (CAB)
8 (CAB)
102 mo. BF OS, CSS 17.0
13.6
153 (55.4) 159 (57.6)
Pts: patients; RT: radiotherapy; Gy: gray; mo.: months; F.U.: follow-up; PSA: serum prostate-specific antigen; N°: number; AS: androgen suppression; yrs: years;
BDFS: biochemical disease free survival; CDFS: clinical disease free survival; GF: goserelin + flutamide; OS: overall survival; CSS: cancer specific survival; DFS:
disease free survival; BF: biochemical failure; DMF: distant metastases failure; CAB: complete androgen blockade; CPFS: clinical progression free survival; BPFS:
biochemical progression free survival: BF: biochemical failure.
Table 2 Combined efficacy results
Outcomes Pts
(RCTs)
RR (95% CI) p-value Het.
(p)
AD
(%)
NNT
BF 3,424 (5) 1.32 (1.09,
1.60)
0.004 0.003 10.1 9-10
CSS 3,128 (4) 1.21 (0.82,
1.79)
0.32 0.09 - -
OS 3,128 (4) 1.09 (0.92,
1.28)
0.28 0.15 - -
DM 2,852 (3) 1.77 (1.16,
2.69)
0.007 0.06 11.5 9
LR 2,852 (3) 1.87 (1.22,
2.86)
0.004 0.10 11.7 9
Pts: patients; RCTs: randomized clinical trials; RR: relative risk; CI: confidence
intervals; Het.: heterogeneity; p: p-value; AD: absolute difference; NNT: number
needed to treat; BF: biochemical failure; CSS: cancer specific survival; OS:
overall survival: LR: local relapse; DM: distant metastases.
Table 3 Meta-regression Analysis
Outcome Predictor p-value
Log RR Median PSA G 7-10 T3-4 Time Delay
BF 0.34 0.35 0.43 0.0003
CSS 0.11 0.81 0.19 0.03
OS 0.50 0.15 0.06 0.03
LR 0.21 0.70 0.18 0.03
DM 0.81 0.23 0.63 0.02
RR: relative risk; G: Gleason score; T: t-size; Time delay: time interval between
the short and the long hormonal treatment duration; BF: biochemical failure;
CSS: cancer specific survival; OS: overall survival: LR: local relapse; DM: distant
metastases.
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patients [7,39] (Figure 2, 3). Conversely, the positive
effect of long term hormonal duration can be partially
driven by the inclusion of those 2 trials including
patients with node-positive disease [34,36]. So, we are
not able to actually exclude a ‘carry-over’ effect due to
the inclusion of such trials with these characteristics.
The mixture of such confounders (such as different cut-
offs in the Gleason score) in trial selection does not
allow to derive clear and definitive conclusions.
Nevertheless, even taking into account all the drawbacks
in correlation and meta-regression estimations of cumulat-
ing few trials, the absolute difference in favour of the
longer HT (and the lower NNT) strongly justifies a pro-
longed treatment strategy. Moreover, the meta-regression
analysis did also show a significant correlation between
the length of the longer strategy and the effect in the
reduction of BF, LR and DM and the improvement of CSS
(Table 3 Figure 2). The latest conclusion allows to care-
fully speculate upon a ‘treat-until-progression’ strategy, at
least in the context of a randomized trial.
Recent reports suggest that the risk of cardio meta-
bolic problems with long-term castration deprivation
therapy could counteract the benefits of hormone ther-
apy, although this has also been questioned. Long term
androgen suppression can reduce the quality of life and
increase the risk of fatal myocardial infarction, fractures,
and the development of a metabolic syndrome. In the
context of neoadjuvant approaches, it has been recently
reported that hormone-therapy is associated with a sig-
nificant increase of all-cause mortality in those patients
with a cardiac comorbidity, but not in those who did
not show any history of cardiovascular disease [40]. This
represent a crucial step-forward in the selection of those
patient who could be considered as appropriate candi-
dates for a longer hormonal suppression.
The radiotherapy component of the combined treat-
ment is crucial: cancer-specific and overall mortality
rates at 10 years are significantly lower with the com-
bined treatment in respect to androgen suppression
alone. Moreover, the survival benefit seem to depend on
the duration of homone-therapy, and was also reported
by the Early Prostate Cancer Programme using adjuvant
antiandrogen treatment as well. In studies with short or
intermediate androgen deprivation of, survival prolonga-
tion has only been reported in subgroups.
At the start of these trials, the standard radiation dose
to the prostate was 70 Gy or less. With the advent of
intensity-modulated and image-guided radiotherapy
techniques, radiation doses of 78 Gy or higher are now
possible, and randomised studies have shown that bio-
chemical relapse-free survival improves with high radia-
tion doses. As a consequence, the overall survival
benefit might further increase further with higher safely
radiation doses [41-44]. Clearly, open issues remain
whether the duration of the hormonal suppression
could eventually affect the outcome when radiation
therapy is administered with higher dosages, and what
should be irradiated (prostate or the whole pelvis).
The general shared consensus is that high risk patients
would better benefit from two to three years of adjuvant
androgen deprivation, while those with intermediate’ risk
prostate cancer from six months of adjuvant androgen
deprivation plus radiotherapy delivered with a dose lower
or equal to 70Gy (for doses higher than 70 Gy the appro-
priate duration of adjuvant androgen deprivation is still
unknown) [16,17]. According to the trial recently published
by Bolla et al, the effect of short-term and long-term
androgen suppression upon five-year mortality is likely to
Reference Outcome Risk Ratio and 95% CI 
Crook et al  IJRBP 2008 CSS
Armstrong et al IJRBP 2010 CSS
Horwitz et al JCO 2008 CSS
Bolla et al NEJM 2009 CSS
0.5 1 2
Favours ST Favours LT
Armstrong et al IJRBP 2010 BF
Lavardiere et al JU 2004 BF
Horwitz et al JCO 2008 BF
Crook et al  IJRBP 2008 BF
Bolla et al NEJM 2009 BF
Figure 2 Combined Results - Primary Outcomes (BF, CSS). CI:
confidence intervals; BF: biochemical failure; CSS: cancer specific
survival; ST: shorter therapy: LT: longer therapy.
Reference Outcome Risk Ratio and 95% CI 
0.5 1 2
Favours ST Favours LT
Crook et al  IJRBP 2008 OS
Armstrong et al IJRBP 2010 OS
Horwitz et al JCO 2008 OS
Bolla et al NEJM 2009 OS
Crook et al  IJRBP 2008 DM
Horwitz et al JCO 2008 DM
Bolla et al NEJM 2009 DM
Crook et al  IJRBP 2008 LR
Horwitz et al JCO 2008 LR
Bolla et al NEJM 2009 LR
Figure 3 Combined Results - Secondary Outcomes (OS, DM,
LR). CI: confidence intervals; OS: overall survival; DM: distant
metastases; LR: local recurrences; ST: shorter therapy: LT: longer
therapy.
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be maintained at ten years [39,45], whereas the short-term
benefit may actually be no longer effective. The intriguing
factor that can help in the daily decision between one strat-
egy over the other is the relative weight of adverse events
and the adverse effects on quality of life between the two
groups of patients; indeed, although no significant differ-
ence in the overall quality of life did emerge between the
two groups in the Bolla et al trial (p = 0.37), a clinically
meaningful difference was present for hot flushes, sexual
interest, and sexual activity [34]. Unfortunately, our analy-
sis could investigate neither the pooled toxicities nor the
quality of life data into a cumulative fashion, given the lack
of a complete reporting in the original trials.
Although the treatment duration seems to significantly
impact upon outcome, it should be acknowledged that
other factors may have a critical role, or may be more
important: indeed, in the recent update of the Crook
et al study, the more relevant weight for benefit seems
related more to the early biochemical response to hor-
monal treatment before radiotherapy, rather than its
overall duration [46]. For these reasons, a critical view
of all data as shown in our analysis (taking into account
all the limitations related to the adopted approach and
methodology) is recommended.
Conclusions
Taking into account the current data available in litera-
ture, and the results reported herein, the significant dif-
ferences in outcome in favour of a longer hormonal
treatment duration do support the adoption of such a
strategy for patients affected by locally advanced pros-
tate cancer, although several limitations should be con-
sidered given the small number of trials included.
Nevertheless, a careful patient selection upon the pre-
sence/absence of cardiovascular and/or metabolic
comorbidities should be adopted, in order to avoid sig-
nifican late-term toxicities. On the contrary, a wide
adoption of a longer administration regardless of the
risk stratification (notwithstanding the results of the
meta-regression analysis) seems in some way not
enough mature, in absence of more reliable data coming
from an individual patient data meta-analysis.
Authors’ contributions section
FCu, EB, DG, and PC conceived the analysis, and super-
vised the calculations; FCu, EB, DG, IS, and PC per-
formed the calculations in a blinded fashion; VV, MM,
EMR, IS, and PC participated in the trials recruitment
and selection process; FCu, EB, SB and PC drafted and
revised the manuscript; DG, CN, PP, GL, PM, FC and
PC did coordinate the overall study process and did pro-
vide the funding. All authors read and approved the
final manuscript.
Acknowledgements
Supported by a grant of the National Ministry of Health and the Italian
Association for Cancer Research (AIRC).
Previous Presentation:
Presented at the 45th ASCO (American Society of Medical Oncology) annual
meeting, Orlando, Florida (US), May 29th- June 2nd, 2009.
Author details
1Department of Medical Oncology, Regina Elena National Cancer Institute,
Roma, Italy. 2Biostatistics, Regina Elena National Cancer Institute, Roma, Italy.
3Medical Oncology, Ospedale ‘Belcolle’, Viterbo, Italy. 4Clinical Oncology Unit,
Istituto Neurotraumatologico Italiano (I.N.I.), Grottaferrata, Rome, Italy.
5Scientiphic Direction, Regina Elena National Cancer Institute, Roma, Italy.
6Medical Oncology, Ospedale San Donato, Arezzo, Italy.
Competing interests
None of the authors have competing interests or potential conflicts with this
work. In particular:
• In the past five years have you received reimbursements, fees, funding, or
salary from an organization that may in any way gain or lose financially from
the publication of this manuscript, either now or in the future? NO
• Do you hold any stocks or shares in an organization that may in any way
gain or lose financially from the publication of this manuscript, either now
or in the future? NO
• Do you hold or are you currently applying for any patents relating to the
content of the manuscript? Have you received reimbursements, fees,
funding, or salary from an organization that holds or has applied for patents
relating to the content of the manuscript? NO
• Do you have any other financial competing interests? NO
Received: 10 January 2010 Accepted: 9 December 2010
Published: 9 December 2010
References
1. Sharifi N, Gulley JL, Dahut WL: Androgen deprivation therapy for prostate
cancer. Jama 2005, 294:238-244.
2. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G,
Bernier J, Kuten A, Sternberg C, et al: Long-term results with immediate
androgen suppression and external irradiation in patients with locally
advanced prostate cancer (an EORTC study): a phase III randomised trial.
Lancet 2002, 360:103-106.
3. Bolla M, van Tienhoven G, de Reijke TM, van den Bergh AC, van der
Meijden AP, Poortmans PM, Gez E, Kil P, Pierart M, Collette L,
Groups EROaG-UT: Concomitant and adjuvant androgen deprivation
(ADT) with external beam irradiation (RT) for locally advanced prostate
cancer: 6 months versus 3 years ADT–Results of the randomized EORTC
Phase III trial 22961. J Clin Oncol (Meeting Abstracts) 2007, 25:5014-.
4. D’Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW: Androgen
suppression and radiation vs radiation alone for prostate cancer: a
randomized trial. Jama 2008, 299:289-295.
5. D’Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW:
6-month androgen suppression plus radiation therapy vs radiation
therapy alone for patients with clinically localized prostate cancer: a
randomized controlled trial. Jama 2004, 292:821-827.
6. Denham JW, Steigler A, Lamb DS, Joseph D, Mameghan H, Turner S,
Matthews J, Franklin I, Atkinson C, North J, et al: Short-term androgen
deprivation and radiotherapy for locally advanced prostate cancer:
results from the Trans-Tasman Radiation Oncology Group 96.01
randomised controlled trial. Lancet Oncol 2005, 6:841-850.
7. Laverdiere J, Nabid A, De Bedoya LD, Ebacher A, Fortin A, Wang CS, Harel F:
The efficacy and sequencing of a short course of androgen suppression
on freedom from biochemical failure when administered with radiation
therapy for T2-T3 prostate cancer. J Urol 2004, 171:1137-1140.
8. Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, Lawton C,
Machtay M, Grignon D: Phase III radiation therapy oncology group
(RTOG) trial 86-10 of androgen deprivation adjuvant to definitive
radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat
Oncol Biol Phys 2001, 50:1243-1252.
9. Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, Hug EB,
Asbell SO, Grignon D: Androgen suppression adjuvant to definitive
Cuppone et al. BMC Cancer 2010, 10:675
http://www.biomedcentral.com/1471-2407/10/675
Page 6 of 8
radiotherapy in prostate carcinoma–long-term results of phase III RTOG
85-31. Int J Radiat Oncol Biol Phys 2005, 61:1285-1290.
10. Roach M, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ, Lawton C,
Valicenti R, Grignon D, Pilepich MV: Short-term neoadjuvant androgen
deprivation therapy and external-beam radiotherapy for locally
advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol
2008, 26:585-591.
11. See WA, Tyrrell CJ: The addition of bicalutamide 150 mg to radiotherapy
significantly improves overall survival in men with locally advanced
prostate cancer. J Cancer Res Clin Oncol 2006, 132(Suppl 1):S7-16.
12. Bria E, Cuppone F, Giannarelli D, Milella M, Ruggeri EM, Sperduti I,
Pinnaro P, Terzoli E, Cognetti F, Carlini P: Does hormone treatment added
to radiotherapy improve outcome in locally advanced prostate cancer?:
meta-analysis of randomized trials. Cancer 2009, 115:3446-3456.
13. Roach M, Lu J, Pilepich MV, Asbell SO, Mohiuddin M, Terry R, Grignon D,
Lawton C, Shipley W, Cox J: Predicting long-term survival, and the need
for hormonal therapy: a meta-analysis of RTOG prostate cancer trials. Int
J Radiat Oncol Biol Phys 2000, 47:617-627.
14. Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J,
Basaria S: Metabolic syndrome in men with prostate cancer undergoing
long-term androgen-deprivation therapy. J Clin Oncol 2006, 24:3979-3983.
15. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS: Risk of fracture after
androgen deprivation for prostate cancer. N Engl J Med 2005,
352:154-164.
16. Mohler J, Bahnson RR, Boston B, Busby JE, D’Amico A, Eastham JA, Enke CA,
George D, Horwitz EM, Huben RP, et al: NCCN clinical practice guidelines
in oncology: prostate cancer. J Natl Compr Canc Netw 8:162-200.
17. Mohler JL: The 2010 NCCN clinical practice guidelines in oncology on
prostate cancer. J Natl Compr Canc Netw 8:145.
18. Goldenberg SL, Klotz LH, Srigley J, Jewett MA, Mador D, Fradet Y, Barkin J,
Chin J, Paquin JM, Bullock MJ, Laplante S: Randomized, prospective,
controlled study comparing radical prostatectomy alone and
neoadjuvant androgen withdrawal in the treatment of localized prostate
cancer. Canadian Urologic Oncology Group. J Urol 1996, 156:873-877.
19. Soloway MS, Sharifi R, Wajsman Z, McLeod D, Wood DP, Puras-Baez A:
Randomized prospective study comparing radical prostatectomy alone
versus radical prostatectomy preceded by androgen blockade in clinical
stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant
Prostate Cancer Study Group. J Urol 1995, 154:424-428.
20. Pignon JP, Hill C: Meta-analyses of randomised clinical trials in oncology.
Lancet Oncol 2001, 2:475-482.
21. Bria E, Milella M, Gelibter A, Cuppone F, Pino MS, Ruggeri EM, Carlini P,
Nistico C, Terzoli E, Cognetti F, Giannarelli D: Gemcitabine-based
combinations for inoperable pancreatic cancer: Have we made real
progress?: a meta-analysis of 20 phase 3 trials. Cancer 2007, 110:525-533.
22. Higgins JPT, Green S: Cochrane handbook for Systematic Reviews of
intervention 4.2.6 [updated sep 2006]. The Cochrane Library Chichester,
UK: John Wiley & Sons, Ltd; 2006, 4.
23. Case LD, Kimmick G, Paskett ED, Lohman K, Tucker R: Interpreting
measures of treatment effect in cancer clinical trials. Oncologist 2002,
7:181-187.
24. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR: Introduction to Meta-
Analysis Chichester, West Sussex, UK: John Wiley & Sons, Ltd. Publication;
2009.
25. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials
1986, 7:177-188.
26. Shuster JJ: Empirical vs natural weighting in random effects meta-
analysis. Stat Med 29:1259-1265.
27. Cochran WG: The combination of estimates from different experiments.
Biometrics 1954, 10:101-129.
28. Deeks JJ: Issues in the selection of a summary statistic for meta-analysis
of clinical trials with binary outcomes. Stat Med 2002, 21:1575-1600.
29. Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, Botella J: Assessing
heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods
2006, 11:193-206.
30. Bria E, Gralla RJ, Raftopoulos H, Cuppone F, Milella M, Sperduti I, Carlini P,
Terzoli E, Cognetti F, Giannarelli D: Magnitude of benefit of adjuvant
chemotherapy for non-small cell lung cancer: meta-analysis of
randomized clinical trials. Lung Cancer 2009, 63:50-57.
31. Parmar MKB, Machin D: Survival analysis: a practical approach Chichester
(England): John Wiley; 1995.
32. Altman DG: Confidence intervals for the number needed to treat. Bmj
1998, 317:1309-1312.
33. Bolla M, Collette L, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff ROM,
Storme G, Bernier J, Kuten A, Piérart M: Ten Year Results of Long Term
Adjuvant Androgen Deprivation with Goserelin in Patients with Locally
Advanced Prostate Cancer Treated with Radiotherapy: A Phase III EORTC
Study. In International Journal of Radiation Oncology & Biology & Physics,
American Society for Therapeutic Radiology and Oncology (ASTRO) 50th Annual
Meeting September 1st, 2008; Boston Edited by: Elsevier 2008, S30-S31.
34. Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J,
Poortmans PM, Gez E, Kil P, Akdas A, Soete G, et al: Duration of androgen
suppression in the treatment of prostate cancer. N Engl J Med 2009,
360:2516-2527.
35. Crook J, Ludgate C, Malone S, Lim J, Perry G, Eapen L, Bowen J,
Robertson S, Lockwood G: Report of a multicenter Canadian phase III
randomized trial of 3 months vs. 8 months neoadjuvant androgen
deprivation before standard-dose radiotherapy for clinically localized
prostate cancer. Int J Radiat Oncol Biol Phys 2004, 60:15-23.
36. Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD,
Venkatesan V, Lawton CA, Rosenthal SA, Sandler HM, Shipley WU: Ten-year
follow-up of radiation therapy oncology group protocol 92-02: a phase
III trial of the duration of elective androgen deprivation in locally
advanced prostate cancer. J Clin Oncol 2008, 26:2497-2504.
37. Armstrong JG, Gillham CM, Dunne MT, Fitzpatrick DA, Finn MA, Cannon ME,
Taylor JC, O’Shea CM, Buckney SJ, Thirion PG: A Randomized Trial (Irish
Clinical Oncology Research Group 97-01) Comparing Short Versus
Protracted Neoadjuvant Hormonal Therapy Before Radiotherapy for
Localized Prostate Cancer. Int J Radiat Oncol Biol Phys .
38. Bria E, Cuppone F, Giannarelli D, Milella M, Ruggeri EM, Sperduti I,
Pinnaro P, Terzoli E, Cognetti F, Carlini P: Does hormone treatment added
to radiotherapy improve outcome in locally advanced prostate cancer?:
meta-Analysis of Randomized Trials. Cancer 2009.
39. Crook J, Ludgate C, Malone S, Perry G, Eapen L, Bowen J, Robertson S,
Lockwood G: Final report of multicenter Canadian Phase III randomized
trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy
before conventional-dose radiotherapy for clinically localized prostate
cancer. Int J Radiat Oncol Biol Phys 2009, 73:327-333.
40. Nanda A, Chen MH, Braccioforte MH, Moran BJ, D’Amico AV: Hormonal
therapy use for prostate cancer and mortality in men with coronary
artery disease-induced congestive heart failure or myocardial infarction.
JAMA 2009, 302:866-873.
41. Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA,
Huddart RA, Jose CC, Matthews JH, Millar J, et al: Escalated-dose versus
standard-dose conformal radiotherapy in prostate cancer: first results
from the MRC RT01 randomised controlled trial. Lancet Oncol 2007,
8:475-487.
42. Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, Lee AK,
Pollack A: Long-term results of the M. D. Anderson randomized dose-
escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008,
70:67-74.
43. Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, von
Eschenbach AC, Kuban DA, Rosen I: Prostate cancer radiation dose
response: results of the M. D. Anderson phase III randomized trial. Int J
Radiat Oncol Biol Phys 2002, 53:1097-1105.
44. Zietman AL, DeSilvio ML, Slater JD, Rossi CJ, Miller DW, Adams JA,
Shipley WU: Comparison of conventional-dose vs high-dose conformal
radiation therapy in clinically localized adenocarcinoma of the prostate:
a randomized controlled trial. JAMA 2005, 294:1233-1239.
45. Souhami L, Bae K, Pilepich M, Sandler H: Impact of the duration of
adjuvant hormonal therapy in patients with locally advanced prostate
cancer treated with radiotherapy: a secondary analysis of RTOG 85-31. J
Clin Oncol 2009, 27:2137-2143.
46. Alexander A, Crook J, Jones S, Malone S, Bowen J, Truong P, Pai H,
Ludgate C: Is biochemical response more important than duration of
neoadjuvant hormone therapy before radiotherapy for clinically
localized prostate cancer? An analysis of the 3-versus 8-month
randomized trial. Int J Radiat Oncol Biol Phys 76:23-30.
Cuppone et al. BMC Cancer 2010, 10:675
http://www.biomedcentral.com/1471-2407/10/675
Page 7 of 8
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/10/675/prepub
doi:10.1186/1471-2407-10-675
Cite this article as: Cuppone et al.: Impact of hormonal treatment
duration in combination with radiotherapy for locally advanced
prostate cancer: Meta-analysis of randomized trials. BMC Cancer 2010
10:675.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Cuppone et al. BMC Cancer 2010, 10:675
http://www.biomedcentral.com/1471-2407/10/675
Page 8 of 8
